We receive funding from a variety of sources that recognize the value of our high-impact research.
Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and Pathology. Yongho Bae (Principal Investigator). NIH/NHLBI. $2,266,072. 9/1/2023-8/1/2027.
Immunomodulatory Therapy After Resuscitation From Cardiac Arrest. Olga Pletnikova (Consultant). NIH. 1/1/2022-12/1/2026.
Disrupting ion channel scaffolding to treat neuropathic pain. Tracey Ignatowski (Co-Investigator). NIH. $1,901,926. 9/1/2019-8/1/2024.
Quantitative Risk Model for Predicting Likelihood of Recurrence for Oral Cavity Cancer. Scott Doyle (Principal Investigator). NIH. $2,003,024. 4/1/2020-3/1/2024.
On the Control of Neuronal Networks through Light-mediated Programming of Genomic Networks. Michal Stachowiak (Principal Investigator). National Science Foundation. 3/1/2021-3/1/2024.
Collaborative Research: Control of Information Processing and Learning in Neuronal Networks through Light-mediated Programming of Genomic Networks. Yongho Bae (Co-Principal Investigator). National Science Foundation. $366,284. 2/1/2021-1/1/2024.
Drug Development Project. Yongho Bae (Principal Investigator). Empire Discovery Institute. $250,000. 11/1/2022-11/1/2023.
Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and Pathology. Yongho Bae (Principal Investigator). NIH/NHLBI. $639,543. 9/1/2022-8/1/2023.
Biomarker Discovery and Validation in PSP. Olga Pletnikova (Contributor). NIH. $576,476. 8/1/2018-4/1/2023.
Networked Nanophotonic Devices for Stem Cell Regulation: From Optogenetics to Optogenomics. Yongho Bae (Co-Principal Investigator). National Science Foundation. $599,067. 8/1/2017-7/1/2022.
Mechanotransduction in Vascular Smooth Muscle: Survivin as a Mediator of Stiffness-Induced Responses. Yongho Bae (Principal Investigator). American Heart Association. $266,000. 7/1/2018-6/1/2022.
“Networked Nanophotonic Devices for Stem Cell Regulation:From Optogenetics to Optogenomics. Michal Stachowiak (Co-Principal Investigator). National Science Foundation. 9/1/2017-9/1/2021.
SBIR Phase II “A Blood-Based Test to Identify Patients with Intracranial Aneurysm”. John Kolega (Principal Investigator). Neurovascular Diagnostics, Inc. $24,891. 8/1/2019-7/1/2021.
Computerized histologic image predictor of cancer outcome. John Tomaszewski (Co-Investigator). NIH/Case. $232,187. 7/1/2016-6/1/2021.
University at Buffalo’s Center for Advanced Technology in Big Data and Health Sciences Total (UBCAT) “Molecular Markers for Dangerous Intracranial Aneurysms”. John Kolega (Principal Investigator). Neurovascular Diagnostics, Inc. $17,387. 7/1/2020-6/1/2021.
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker The goal of this study to clarify mechanism of TDP-43 proteinopathy and perform target validation studies and develop biomarkers for ALS-FTD. Olga Pletnikova (Contributor). NIH. $250,000. 4/1/2016-3/1/2021.
